宫颈癌术前新辅助化疗的临床疗效观察

Evaluation of Clinical Efficiency of Neoadjuvant Chemotherapy in the Treatment of Patients with Cervical Carcinoma

目的探讨新辅助化疗在早期宫颈癌术前治疗中的应用及疗效。方法收集29例早期宫颈癌,术前给以BIP方案的新辅助化疗,化疗14 d后评价其疗效。结果化疗总有效率为79.3%,CR 34.5%(10/29),PR 44.8%(13/29),SD 20.7%(6/29),PD 0(0/29),其中Ⅰb1期有效率100.0%(5/5),Ⅰb2期有效率88.9%(16/18),Ⅱa期有效率50.0%(3/6);宫颈肿瘤<4 cm有效率90.9%,≥4 cm有效率72.2%。结论新辅助化疗作为早期宫颈癌术前治疗,可以明显缩小或消退宫颈肿瘤,减少术后宫旁浸润,淋巴结转移,降低术后并发症发生率,减少术后复发。

Objective To evaluate the efficiency of neoadjuvant chemotherapy in the treatment of early cervical carcinoma.Methods 29 patients with early cervical carcinoma were treated with BIP regimen of neoadjuvant chemotherapy before operation.14 days after chemotherapy,the evaluation was evaluated.Results The total response rate of neoadjuvant chemotherapy was 79.3%,CR 34.5%,PR 44.8%,SD 20.7%,PD 0.The response rates of stageⅠb1,Ⅰb2 andⅡa were 100.0%,88.9%,50.0%,respectively.The response rates of patients with cervical tumor 4 cm and ≥ 4 cm were 90.9% and 72.2%,respectively.Conclusion As a kind of preoperative therapy of early cervical carcinoma,neoadjuvant chemotherapy can shrink significantly the cervical tumor,reduce parametrium invasion and lymph node metastasis,and decrease the postoperative complications and the postoperative recurrence.